Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00641992
Other study ID # PFP-ALA
Secondary ID
Status Completed
Phase N/A
First received March 12, 2008
Last updated March 17, 2008
Start date May 1999
Est. completion date April 2000

Study information

Verified date March 2008
Source Universidad Autonoma de San Luis Potosí
Contact n/a
Is FDA regulated No
Health authority Mexico: National Institute of Public Health, Health Secretariat
Study type Observational

Clinical Trial Summary

Amebic liver abscess is the most frequent extra-intestinal form of the amoebiasis; actually the factors for predicting failure in the medical treatment are not clear. We conducted trial for determining the clinical value of paraclinical factor in this issue.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date April 2000
Est. primary completion date April 2000
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 80 Years
Eligibility Inclusion Criteria:

1. Clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess.

2. Both genders

3. Older 15 years

Exclusion Criteria:

1. Clinically suspected piogenous liver abscess

2. Positive hemoculture

3. Negative ELISA for amoebic antigens

4. Immunosupresion (HIV)

5. Abdominal or biliary surgery antecedents

6. Abdominal neoplasia antecedents

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Mexico Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán". Mexico DF
Mexico Faculty of Medicine, Universidad Autónoma de San Luis Potosí San Luis Potosi

Sponsors (4)

Lead Sponsor Collaborator
Universidad Autonoma de San Luis Potosí Hospital Central "Dr. Ignacio Morones Prieto", Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Universidad Nacional Autonoma de Mexico

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Failure of medical treatment Day 4 Yes